Neurocrine Biosciences to Acquire Soleno Therapeutics for $2.9 Billion in Cash at $53.00 Per Share
SLNO sits 78% above its 52-week low of $29.43 on elevated volume (2.1× avg).
Summary
Soleno Therapeutics has entered into a definitive merger agreement to be acquired by Neurocrine Biosciences for $53.00 per share in cash, valuing the company at approximately $2.9 billion. The acquisition, unanimously recommended by Soleno's Board, will integrate VYKAT XR into Neurocrine's portfolio.
Key Events · M&A and Partnerships · SLNO
-
Definitive Merger Agreement Signed
Soleno Therapeutics entered into an Agreement and Plan of Merger with Neurocrine Biosciences, Inc. and its subsidiary, Sigma Merger Sub, Inc., on April 5, 2026.
-
Cash Tender Offer at Significant Premium
Neurocrine will commence a cash tender offer to acquire all outstanding shares of Soleno common stock at a price of $53.00 per share. This represents a premium of approximately 34% to Soleno's closing share price on April 2, 2026, and 51% to its 30-day volume-weighted average price.
-
Total Transaction Value
The acquisition is valued at approximately $2.9 billion in total equity.
-
Board Recommendation and Shareholder Support
Soleno's Board of Directors unanimously recommends that stockholders accept the offer. Principal stockholders, Anish Bhatnagar and James Mackaness, holding approximately 1.01% of outstanding shares, have entered into Tender and Support Agreements to tender their shares.
Analysis · SLNO · Life Sciences
This 8-K filing announces a definitive agreement for Neurocrine Biosciences to acquire Soleno Therapeutics for $53.00 per share in cash, representing a total transaction equity value of $2.9 billion. This is a highly significant event for Soleno shareholders, as the offer price represents a substantial premium over recent trading prices and the acquisition fundamentally alters the company's future. The unanimous recommendation by Soleno's Board and the tender and support agreements from principal stockholders underscore the strong internal backing for the deal. This transaction provides immediate and certain value to shareholders and integrates Soleno's key product, VYKAT XR, into a larger biopharmaceutical company with established commercial infrastructure, promising expanded reach for the therapy.
At the time of this filing, SLNO was trading at $52.50 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $2B. The 52-week trading range was $29.43 to $90.32. This filing was assessed with positive market sentiment and an importance score of 10 out of 10.